Mission achieves milestone


United Kingdom

Mission Therapeutics Ltd has reached an important threshold in a three-year old collaboration with AbbVie Inc aimed at degrading the toxic proteins in Alzheimer’s and Parkinson’s diseases. The event was the selection of two enzyme targets for the development of new small molecule drugs for these diseases, which are the most common neurological disorders worldwide. It triggered a $20 million milestone payment to Mission, announced on 9 August.